A Phase II/III Study of CS-8958 in Pediatric Patients -A randomized double-blind controlled study of CS-8958 comparing with oseltamivir phosphate in patients with influenza virus infection aged 9 years or younger

Trial Profile

A Phase II/III Study of CS-8958 in Pediatric Patients -A randomized double-blind controlled study of CS-8958 comparing with oseltamivir phosphate in patients with influenza virus infection aged 9 years or younger

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Laninamivir (Primary) ; Oseltamivir
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 05 Apr 2010 Results published in Antimicrobial agents and chemotherapy.
    • 10 Aug 2009 Top-line results reported in a Biota Holdings media release.
    • 10 Aug 2009 Data from this trial will be used in the NDA submission to the US FDA, according to a Daiichi Sankyo Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top